BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 8404961)

  • 1. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
    Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
    Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
    Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
    Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
    Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
    Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B; Forssell-Aronsson E; Tisell LE; Nilsson O; Fjalling M; Ahlman H
    Br J Cancer; 1996 Mar; 73(6):770-5. PubMed ID: 8611378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 111In-octreotide scintigraphy in oncology.
    Krenning EP; Kwekkeboom DJ; Reubi JC; van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
    Digestion; 1993; 54 Suppl 1():84-7. PubMed ID: 8359573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.
    Bakker WH; Krenning EP; Reubi JC; Breeman WA; Setyono-Han B; de Jong M; Kooij PP; Bruns C; van Hagen PM; Marbach P
    Life Sci; 1991; 49(22):1593-601. PubMed ID: 1658516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
    Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
    Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.
    Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S
    Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.
    Janson ET; Westlin JE; Ohrvall U; Oberg K; Lukinius A
    J Nucl Med; 2000 Sep; 41(9):1514-8. PubMed ID: 10994731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview.
    Kwekkeboom DJ; Krenning EP
    Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor imaging in intracranial tumours.
    Schmidt M; Scheidhauer K; Luyken C; Voth E; Hildebrandt G; Klug N; Schicha H
    Eur J Nucl Med; 1998 Jul; 25(7):675-86. PubMed ID: 9662588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
    Seifert JK; Görges R; Bockisch A; Junginger T
    Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 111In-octreotide scintigraphy in oncology.
    Krenning EP; Kwekkeboom DJ; Reubi JC; Van Hagen PM; van Eijck CH; Oei HY; Lamberts SW
    Metabolism; 1992 Sep; 41(9 Suppl 2):83-6. PubMed ID: 1355591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.